Novel therapeutic approaches for hepatocellulcar carcinoma: Fact and fiction

Yuan-Yuan Zhang; Hua-Xiang Xia, Harry; Keeffe, Emmet B.
March 2008
World Journal of Gastroenterology;3/21/2008, Vol. 14 Issue 11, p1641
Academic Journal
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and accounts for 80%-90% of this class of malignancy. So far, understanding of its pathogenesis and effective therapeutic methods are rather limited. In this issue, 11 invited review articles are published to address current advance of underlying molecular mechanisms for the deve-lopment of HCC, and novel therapeutic approaches for HCC. This series of review articles provide an in-depth unders-tanding of HCC that has led to or may lead to the development of novel therapies for HCC.


Related Articles

  • Points of Therapeutic Intervention Along the Wnt Signaling Pathway in Hepatocellular Carcinoma. Nambotin, Sarah B.; Wands, Jack R.; Kim, Miran // Anti-Cancer Agents in Medicinal Chemistry;2011, Vol. 11 Issue 6, p549 

    Hepatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide. However, there is little known about targeted therapeutics for the treatment of this devastating tumor. Among the growth factor signaling cascades deregulated in HCC, evidences suggest that the...

  • Harnessing the RNA interference pathway to advance treatment and prevention of hepatocellular carcinoma. Arbuthnot, Patrick; Thompson, Liam Jed; Piscaglia, Anna C. // World Journal of Gastroenterology;3/21/2008, Vol. 14 Issue 11, p1670 

    Primary liver cancer is the fifth most common malignancy in the world and is a leading cause of cancer-related mortality. Available treatment for hepatocellular carcinoma (HCC), the commonest primary liver cancer, is rarely curative and there is a need to develop therapy that is more effective....

  • SORAFENIB IN HEPATOCELLULAR CARCINOMA: HYPE OR HOPE? Ghatak, Somsuvra B.; Panchal, Shital J. // International Journal of Pharmacy & Pharmaceutical Sciences;Jul2011 Supplement 4, Vol. 3, p1 

    Hepatocellular carcinoma (HCC) is the fifth most commonly prevalent tumor worldwide and continues to have a dismal prognosis with an expected survival of 4-6 months. Effective systemic treatment options for advanced HCC are limited and its management is still a challenge to the physicians since...

  • Living Donor Liver Transplantation: Cumulative Insights from Taiwan. Palaniappan, Nagarajan; Chao-Long Chen // Cell & Tissue Transplantation & Therapy;2016, Vol. 8, p5 

    This review portrays the living donor liver transplantation (LDLT) scenario in Asia with emphasis on the role played by Taiwan in meeting the objective of offering LDLT as a life-saving procedure in the treatment of end-stage liver disease. In the West, although LDLT has been offered as a...

  • Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma. Tanaka, Shinji; Arii, Shigeki // International Journal of Clinical Oncology;Apr2006, Vol. 11 Issue 2, p82 

    Hepatocellular carcinoma (HCC) is well known as a typical angiogenic tumor, especially in the moderately to poorly differentiated type. Such clinicopathological characteristics are not only useful for imaging diagnosis but are also applicable to the treatment of HCC. In addition, recent...

  • The expression and regulation of DFNA5 in human hepatocellular carcinoma DFNA5 in hepatocellular carcinoma. Wang, Cong-Jun; Tang, Lin; Shen, Dong-Wei; Wang, Chao; Yuan, Qiong-Ying; Gao, Wei; Wang, Yong-Kun; Xu, Rong-Hua; Zhang, Hui // Molecular Biology Reports;Dec2013, Vol. 40 Issue 12, p6525 

    Hepatocellular carcinoma is a primary malignancy of hepatocytes which accounts for 80 % of all primary liver cancers. DFNA5 has been identified as a tumor suppressor gene with an important role in several frequent forms of cancers, while little is known about its role in hepatocellular...

  • Molecular targeted therapy for hepatocellular carcinoma. Thomas, Melanie // Journal of Gastroenterology;2009 Supplement 19, Vol. 44, p136 

    A majority of patients with HCC present with advanced disease and are not candidates for liver transplantation, surgical resection, or regional therapy. Systemic cytotoxic chemotherapy agents are minimally effective, can have significant toxicity, and have not been shown to improve patient...

  • Optimal treatment strategy in extremely elderly patients with hepatocellular carcinoma. Ruzzenente, A.; Pachera, S.; Iacono, C.; Valdegamberi, A.; Nicoli, P.; Campagnaro, T.; Piccirillo, G.; Guglielmi, A. // BMC Geriatrics;2009 Supplement 1, Vol. 9, Special section p1 

    Background and objective The hepatocellular carcinoma (HCC) is a frequent cancer worldwide. This disease is more frequent in patients over 70 years and only few papers in literature analyze the clinical characteristics and the survival of elderly patients with HCC. The aim of this study is to...

  • Gastric injury from Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction? Gates, Vanessa; Hickey, Ryan; Marshall, Karen; Williams, Melissa; Salzig, Krystina; Lewandowski, Robert; Salem, Riad // European Journal of Nuclear Medicine & Molecular Imaging;Dec2015, Vol. 42 Issue 13, p2038 

    Purpose: Radioembolization with Y microspheres is a locoregional radiation therapy for unresectable hepatic neoplasm. Non-target delivery of Y microspheres resulting in gastrointestinal (GI) symptoms is a recognized complication; there is minimal knowledge regarding the radiation effect to the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics